A panel of experts has crafted guidance for clinical use of Aduhelm (aducanumab), the first targeted treatment for Alzheimer’s disease recently granted accelerated approval by the U.S. Food and Drug Administration (FDA). The recommendations include criteria for determining those patients most appropriate for this once-monthly infusion treatment, and for monitoring safety with its use. The guidelines are in the report “Aducanumab: Appropriate Use Recommendations,” published in The Journal of Prevention of Alzheimer’s Disease. “Aducanumab [Aduhelm] has been…
You must be logged in to read/download the full post.
The post #AAIC21 – Expert Group Publishes Guidance on Aduhelm’s Use appeared first on BioNewsFeeds.